Business Context and Reporting Period
Company: Jupiter Neurosciences, Inc. (JUNS)
Filing Type: Form 8-K (Current Report)
Date of Report: May 20, 2026
Event: Announcement of a non-binding Term Sheet with PharmAla Biotech Holdings Inc. regarding a potential licensing transaction for the U.S. rights to ALA-002, a next-generation MDMA formulation.
Key Financial Metrics and Transaction Terms
This filing details proposed transaction terms rather than historical financial performance. Key financial figures associated with the potential deal include:
- Upfront Consideration: Total of $3,333,333 (comprised of $1,500,000 cash and $1,833,333 in equity securities).
- Escrow Deposit: $600,000 deposited by Jupiter Neurosciences, credited against upfront cash at closing or payable as a reverse termination fee if no definitive agreement is executed within 90 days.
- Development Milestones: $3,333,333 upon Phase 3 initiation; $20,000,000 upon FDA approval.
- Commercialization Milestones: $10,000,000, $30,000,000, and $33,333,333 upon achieving U.S. annual net sales thresholds of $333.3M, $1.0B, and $2.0B, respectively.
- Royalties: Perpetual 3% royalty on U.S. net sales following achievement of all commercialization milestones.
Note: The filing does not provide current revenue, profit, cash flow, or debt figures for Jupiter Neurosciences, Inc.
Material Changes and Transaction Structure
The filing represents a potential material change in the Company's asset portfolio and capital structure, contingent on the execution of definitive agreements.
- Asset Acquisition: Potential acquisition of exclusive, perpetual U.S. rights to ALA-002, including IP, regulatory files, and inventory.
- Equity Issuance: Potential issuance of equity securities valued at $1,833,333 to PharmAla, subject to a 180-day lock-up period.
- Exclusivity: A 90-day exclusivity period (subject to extension) during which PharmAla cannot solicit competing U.S. transactions.
- Timeline: Parties intend to enter into a definitive agreement within 90 days of the Term Sheet date.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The Company intends to negotiate definitive agreements within 90 days. The transaction is non-binding, and there is no assurance that a definitive agreement will be reached or that the transaction will close.
Key Risks and Contingencies:
- Execution Risk: The Term Sheet is non-binding; definitive agreements are subject to due diligence, negotiation, and shareholder/regulatory approvals.
- Termination Fee: If no definitive agreement is executed within 90 days (subject to fault-based carve-outs), the $600,000 escrow is payable to PharmAla as a reverse termination fee.
- Regulatory and Clinical Risk: Future milestones depend on successful clinical trials (Phase 3) and FDA approval, which are not guaranteed.
- Financing Risk: The Company's ability to fund development and commercialization activities remains a risk factor.
Investor Verification Checklist
- Verify the execution of a definitive agreement within the 90-day window to confirm the transaction proceeds.
- Review the Company's current cash position to assess the ability to fund the $1.5M upfront cash payment and ongoing development costs.
- Monitor the status of the $600,000 escrow deposit and the conditions under which it may be forfeited as a termination fee.
- Confirm the terms of the equity issuance, including the specific number of shares and the impact on existing shareholder dilution.
- Assess the clinical data and regulatory status of ALA-002 to evaluate the likelihood of achieving the $23.3M+ in potential development milestones.